

High expression of a specific T-cell receptor γ transcript in epithelial cells of the prostate

MAGNUS ESSAND*, GEORGE VASMATZIS*, ULRICH BRINKMANN*, PAUL DURAY†, BYUNGKOOK LEE*,
AND IRA PASTAN*‡

*Laboratory of Molecular Biology, Division of Basic Sciences, and †Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Building 37, Room 4E16, Bethesda, MD 20892

Contributed by Ira Pastan, May 28, 1999

ABSTRACT We have identified expression of T-cell receptor γ chain (TCR γ) mRNA in human prostate and have shown that it originates from epithelial cells of the prostate and not from infiltrating T-lymphocytes. In contrast, the T-cell receptor δ chain (TCR δ) gene is silent in human prostate. The major TCR γ transcript in prostate has a different size than the transcript expressed in thymus, spleen, and blood leukocytes. It is expressed in normal prostate epithelium, adenocarcinoma of the prostate, and the prostatic adenocarcinoma cell line LNCaP. The RNA originates from an unrearranged TCR γ locus, and it is initiated within the intronic sequence directly upstream of the J γ 1.2 gene segment. The prostate-specific TCR γ transcript consists of the J γ 1.2 and C γ 1 gene segments, and it has an untranslated sequence including a polyadenylation signal and poly(A) sequence at the 3' end. The finding that prostate epithelial cells express a high level of a transcript from a gene that was thought to be exclusively expressed by T-lymphocytes is highly unexpected.

The database of expressed sequence tags (dbEST) is a division of GenBank that contains sequence data and other information on single-pass cDNA sequences, or expressed sequence tags (ESTs). The sequences in dbEST (<http://www.ncbi.nlm.nih.gov/dbEST>) originate from cDNA libraries, each of which is usually prepared from a particular cell type, organ, or tumor. We have previously described how the dbEST database can be used to identify genes that are specifically and highly expressed in the human prostate (1). In clustering of human prostate ESTs, we found many ESTs representing the untranslated 3' end of the T-cell receptor γ chain (TCR γ) but not ESTs representing the T-cell receptor δ chain (TCR δ), α chain (TCR α), or β chain (TCR β). ESTs representing the TCR γ transcript were found both in normal prostate and prostate cancer libraries. The prostate expression was unexpected, leaving two possibilities open. The TCR γ transcript expressed in the prostate could originate from infiltrating $\gamma\delta$ T-lymphocytes, or it could originate from other cell types in the prostate.

The human TCR γ locus is located on chromosome 7, p15-p14 (2, 3). The TCR γ gene is composed of variable (V), joining (J), and constant (C) gene segments that undergo a series of rearrangements to form functionally active genes in mature $\gamma\delta$ T-lymphocytes. In the human germline, 14 V γ gene segments have been identified and divided into four separate subgroups based on sequence homology (4, 5). There are five J γ gene segments organized in two subgroups (J γ 1 and J γ 2) and two different C γ genes (C γ 1 and C γ 2). The TCR γ gene is normally coexpressed together with TCR δ in $\gamma\delta$ T-

lymphocytes. Expression of TCR genes has so far been limited to cells from lymphoid tissues.

In this paper, we focused our studies on the nature of the full-length prostate TCR γ transcript and on determining whether the transcript originates from prostate cells or from $\gamma\delta$ T-lymphocytes infiltrating the human prostate. We show that prostate-specific TCR γ transcripts are expressed in epithelial cells within the acinar ducts of the prostate as well as in prostate cancer and the prostatic adenocarcinoma cell line LNCaP. The predominant transcript is a TCR J γ 1.2-C γ 1 transcript that originates from an unrearranged TCR γ locus.

MATERIALS AND METHODS

RNA Dot Blot and Northern Blot Hybridizations. RNA dot blot (RNA master blot, CLONTECH) and Northern blot analysis (MTN, CLONTECH) were performed on a variety of human tissues. Northern blot analysis also was performed on mRNA from prostate adenocarcinoma cell lines LNCaP and PC-3 (American Type Culture Collection). Isolation of poly(A) RNA was carried out by using the FastTrack kit (Invitrogen). RNA was electrophoresed on a 1% agarose gel and was transferred to nylon-based membranes (GeneScreen Plus, DuPont), according to established procedures (6). A cDNA probe specific for the untranslated 3' end [3' untranslated region (3'UTR)] of the TCR γ transcript was made from EST plasmid ng79d11 (Genome Systems, St. Louis). A probe specific for the constant domain of the TCR γ transcript (TCR C γ) was made from LNCaP cDNA, and a probe for the constant domain of the TCR δ transcript (TCR C δ) was made from a TCR δ plasmid, donated by Ilan Kirch (Naval Hospital, Bethesda, MD). A human β -actin probe was used as a quantity control of the mRNA preparations. Probes were labeled with ³²P by random primer extension (Lofstrand Laboratories, Gaithersburg, MD) to a specific activity of 1 μ Ci/ng (1 Ci = 37 GBq). The RNA membranes were blocked for 2 hours at 45°C in hybridization solution containing 50% formamide (Hybrisol I, Oncor, Gaithersburg, MD) and then were probed for 15 hours at 45°C with 20 μ Ci cDNA in 20 ml of hybridization solution. The membranes were washed twice for 15 minutes at room temperature in 2 \times standard saline citrate (SSC)/0.1% SDS and twice for 20 minutes at 55–65°C in 0.1% SSC/0.1% SDS. The membranes were exposed to an imaging film (X-Omat, Kodak) at –80°C before development.

RNA *In Situ* Hybridization. The TCR γ constant domain and the TCR γ untranslated 3' end nucleotide sequence is amplified by reverse transcriptase-PCR (RT-PCR) from LNCaP

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

PNAS is available online at www.pnas.org.

Abbreviations: EST, expressed sequence tag; dbEST, database of ESTs; TCR γ , T-cell receptor γ chain; UTR, untranslated region; RT, reverse transcriptase; RACE, rapid amplification of cDNA ends; kb, kilobase.

Data deposition: The sequence reported in this paper has been deposited in the GenBank database (accession no. AF151103).

*To whom reprint requests should be addressed. E-mail: pasta@helix.nih.gov.

mRNA, were cloned into pBluescript II SK (+) (Stratagene), and were verified by DNA sequencing. Antisense and sense TCR γ ³⁵S-riboprobes were made by T7 and T3 RNA polymerase, respectively. Paraffin blocks of eight archived cases of prostatic transurethral resection specimens from the National Cancer Institute were retrieved. Cases were selected that included both malignant and benign prostatic ducts. Average age of the cases was 69, and Gleason scores of the tumor ranged from 3 + 3 = 6/10 to 4 + 5 = 9/10. The blocks were processed on glass slides and were hybridized by using the riboprobes (Molecular Histology, Gaithersburg, MD). After hybridization, the slides were counterstained with hematoxylin and eosin and were examined by using a Zeiss Axiophot Microscope equipped with a variable condenser providing bright field and dark field.

RT-PCR Analysis. Single stranded cDNAs were prepared from 150–250 ng of LNCaP and PC-3 poly(A) mRNA, respectively, by using oligo(dT) priming (Amersham Pharmacia). PCR primers were designed to amplify different portions of the TCR γ transcript. To amplify cDNA only and not trace amounts of genomic DNA, which may be present in the mRNA preparations, primer pairs were always combined to generate PCR products spanning two or more exons. One PCR was set up to amplify either of the two TCR γ constant domain genes, C γ 1 or C γ 2, with a forward primer in exon CI (TCRC γ .F) and a reverse primer in exon CIII (TCRC γ .R4) (Table 1). Variable-to-constant domain-spanning PCRs were set up by using forward primers specific to each of the four subgroups of TCR γ variable gene segments (TCRV γ I.F, TCRV γ II.F, TCRV γ III.F, TCRV γ IV.F) in combination with a reverse primer in the TCR γ constant gene segment (TCRC γ .R1) (Table 1). Wax-mediated, hot-start PCRs were conducted for 30 cycles by using high-fidelity PCR components (Expand, Boehringer-Mannheim). The PCR products were analyzed on 1.2% agarose gels with 0.5 μ g/ml of ethidium bromide. Specific PCR products were gel purified (Qiagen, Chatsworth,

CA), T/A cloned (Invitrogen), and sequenced on an automated capillary sequencer (Perkin-Elmer) by using Perkin-Elmer's dRhodamine terminator cycle sequencing kit.

Analysis of TCR γ VJ Gene Rearrangement. Genomic DNA was prepared from 5 \times 10⁷ LNCaP cells according to established procedures (6). A set of 12 PCRs was performed, each with a forward primer from one of the four subgroup of V γ gene segments (TCRV γ I.F, TCRV γ II.F, TCRV γ III.F, TCRV γ IV.F) in combination with a reverse primer from one of the three J γ 1 gene segments (TCRJ γ 1.1.R, TCRJ γ 1.2.R, TCRJ γ 1.3.R) (Table 1). Hot start PCRs were conducted for 30 cycles by using 500 ng of genomic DNA, and the PCRs were examined on 1.2% agarose gels with 0.5 μ g/ml of ethidium bromide. Human placenta DNA (CLONTECH) was used as a positive control of the primers, and PCR amplification of J γ 1.1 to J γ 1.2 genomic DNA was performed as a positive control of the template.

Primer-Extension Analysis of RNA. The start point of the prostate TCR γ transcript was determined by primer-extension analysis of LNCaP mRNA. mRNA (5 μ g) was mixed with 0.08 pmol of ³²P-end labeled TCR γ .R2 primer, annealing 48–75 nucleotides from the 5' end of C γ 1. The analysis was carried out by using 20 units of Moloney Murine Leukemia Virus (MMLV)-reverse transcriptase (Superscript, GIBCO/BRL), according to established procedure (7). The sample was electrophoresed on a 6% polyacrylamide-urea DNA sequencing gel in parallel with a ³²P-end labeled molecular weight marker (*Msp*I-digested pBR322, Lofstrand Laboratories). After electrophoresis, the gel was blotted to Whatman paper and was dried and subjected to autoradiography.

5' Rapid Amplification of cDNA Ends (RACE) PCR Analysis. Double-stranded cDNA was made from 500 ng of LNCaP poly(A) mRNA by using the Marathon cDNA amplification kit (CLONTECH) and 25 pmol of the TCR γ gene-specific primer (TCRC γ .R3) (Table 1). Marathon-adapters then were ligated to the ends of the synthesized cDNA. Rapid amplification of the 5'-cDNA ends (5'-RACE) PCR was conducted by using a gene-specific primer (TCRC γ .R2) (Table 1), annealing upstream of the primer used for reverse transcription, and an adapter-specific primer. Hot start conditions were applied (Advantage, CLONTECH), and the PCR products were analyzed and cloned as described for the RT-PCR analyses. DNA from the 5'-RACE PCR analytic gel was transferred to a nylon membrane, and a ³²P-end labeled primer (TCRC γ .R1) (Table 1) hybridizing further upstream was applied to identify possible bands not detected by ethidium bromide/UV-light.

In Vitro Transcription-Coupled Translation. The complete prostate TCR γ transcript, as obtained by RT-PCR and 5'-RACE PCR, was amplified by RT-PCR, was cloned into pBluescript II SK (+) (Stratagene), and was sequenced and examined in an *in vitro* transcription-coupled translation system, using T7 RNA polymerase and wheat germ extract (TNT, Promega). ³⁵S-Met (ICN) was incorporated in the reaction for visualization of translated products. The reaction was analyzed under reducing condition on a polyacrylamide gel (16.5% Tris/Tricine, Bio-Rad) together with a pre-stained marker (GIBCO/BRL). The gel was dried and subjected to autoradiography.

RESULTS

Prostate ESTs Representing TCR γ Were Identified by Database Analysis. We have identified 23 TCR γ ESTs, from 20 cDNA clones, derived from six tumor and two normal prostate cDNA libraries. The TCR γ composite sequence from assembly of prostate ESTs has 76 nucleotides of TCR γ constant domain sequence and 448 nucleotides of untranslated 3' region sequence and poly(A) sequence. By alignment of the prostate ESTs to mature TCR γ transcripts from cell lines established from peripheral blood T-lymphocytes (GenBank

Table 1. Primers (\rightarrow) used for analysis of the prostate TCR γ transcript

Name	Annealing	Primer Sequence 5' -> 3'
1. TCRV γ I.F	V γ , subgroup I	AACTTGGGAAGGGRGAACRAAGTCAGTC
2. TCRV γ II.F	V γ , subgroup II	AGTACTAAAACGCTGTCAAAAACAGCC
3. TCRV γ III.F	V γ , subgroup III	TTGGACTTGGATTATCAAAAAGTGG
4. TCRV γ IV.F	V γ , subgroup IV	TTGGGCAGTTGGAACAACCTGAAA
5. TCRC γ .F	C γ , exon CI	GATAACAACACTTGATGCAGATGTTTCC
6. TCRC γ .R1	C γ , exon CI	GGGAACATCTGCATCAAGTTGTTTATC
7. TCRC γ .R2	C γ , exon CI	CTGGAGCTTTGTTTCAGCAATGGAAGG
8. TCRC γ .R3	C γ , exon CI	CTCAAGAAGACAAAGGTATGTTCCAGC
9. TCRC γ .R4	C γ , exon CIII	TTATGATTTCTCTCCATTGCAGCAG
10. TCRJ γ 1.1.R	J γ 1.1	GAAGTTACTATGAGCTTAGTCCCTT
11. TCRJ γ 1.2.R	J γ 1.2	AAGCTTTGTTCCGGGACCAAATAC
12. TCRJ γ 1.3.R	J γ 1.3	TACCTGTGACAACAAGTGTGTTTC

R=A+G

accession nos. M16768, M16804, and M30894), we found that the prostate EST composite sequence is identical to the TCR γ transcript from peripheral blood T-lymphocytes. The dbEST database analysis indicates that the TCR γ gene is highly transcribed in human prostate.

Expression of TCR γ (3'UTR) in Human Prostate Verified by RNA Dot Blot. To analyze the transcriptional activity TCR γ gene in human prostate, a cDNA probe from the untranslated 3' end (3'UTR) of the TCR γ transcript was assayed on mRNA from 50 different human tissues (Fig. 1A). We verified that normal prostate (position C7) expresses TCR γ mRNA, and we further observed that prostate has by far the strongest expression of all tissues represented on the dot blot membrane. TCR γ gene expression also was found in small intestine (E3), spleen (E4), thymus (E5), peripheral leukocyte (E6), lymph node (E7), bone marrow (E8), and lung (F2).

Northern Blot Shows Two Size-Specific TCR γ Transcripts in Human Prostate. Northern blot hybridization using the 3'UTR probe revealed that prostate has two TCR γ transcripts of \approx 1.1 and 2.8 kilobases (kb) (Fig. 1B, lane 3) whereas the predominant transcript in spleen, thymus, small intestine, and blood leukocytes is 1.5 kb. A transcript size of 1.5 kb is consistent with TCR γ mRNA from $\gamma\delta$ T-lymphocytes [GenBank accession nos. M16768, M16804 (8), and M30894 (9)]. Because the database analysis indicated that a constant domain of TCR γ is part of the prostate transcript, we also used a TCR γ constant domain probe (TCR C γ). We found the same 1.1- and 2.8-kb bands in the prostate (Fig. 2A, lane 3).

Prostate Cells Expressing TCR γ Do Not Express TCR δ or CD3 Transcripts. TCR γ chain protein is normally coexpressed with the TCR δ chain protein. Because the TCR γ gene is transcriptionally active in human prostate, we went on to analyze the transcriptional activity of the TCR δ gene. The dbEST was analyzed (<http://www.ncbi.nlm.nih.gov/BLAST>) by using the TCR δ transcript nucleotide sequence. ESTs from prostate cDNA libraries did not match any part of the TCR δ chain transcript. Furthermore, Northern blot analysis did not detect any prostate expression of TCR δ mRNA (Fig. 2B, lane 3). We conclude that the TCR δ gene is silent in prostate. As expected, TCR δ transcripts are expressed in spleen, thymus, and blood leukocytes (Fig. 2B).

LNcaP Cells, but not PC-3 Cells, Express the Prostate-Specific TCR γ Transcripts. Given that TCR γ mRNA is expressed in normal prostate, we next analyzed whether it is also expressed in prostate cancer. The prostate-specific 1.1-kb transcript was found in mRNA preparations from LNcaP but not in mRNA preparations from PC-3 (Fig. 2C). The prostate-specific 2.8-kb transcript, expressed in normal prostate, is also present in LNcaP, although to a much lesser degree.

RNA *in Situ* Hybridization Shows TCR γ Expression in Prostate Epithelial Cells. The prostate consists of acinar glandular tissue with variable and mixed population of simple duct lining epithelial cells, ranging to complex hyperplastic ducts in the glandular compartments. These compartments are tightly connected to smooth muscle cells, fibroblasts, and other cell types in the prostate stroma. To determine the cellular localization of the human prostate TCR γ expression, RNA *in situ* hybridization was carried out with TCR(C γ -3'UTR) sense and antisense riboprobes. We found that TCR γ mRNA is highly expressed in epithelial cells within the acinar ducts of the prostate whereas stromal cells and other cell types in the prostate are negative (Fig. 3A and C). TCR γ expression also was detected in hyperplastic and neoplastic areas of the prostate. The expression in benign and neoplastic acinar epithelium is comparable (data not shown). TCR γ expression could not be observed in human kidney tissue (Fig. 3E) or in human brain (data not shown).

The Prostate TCR γ Transcript Contains C γ 1 but not any V γ Genes. After we had established the TCR $\gamma\delta$ expression profile in the prostate, we went on to characterize the predominant, 1.1-kb, prostate-specific TCR γ transcript. The LNcaP cell line was used for the characterization because one cannot exclude the possibility of mRNA contamination from infiltrating T-cells in the mRNA preparations extracted from bulk prostate tissue. We knew from database analysis that the 3' end sequence of the prostate TCR γ transcript is identical to that from peripheral blood leukocytes and that the location of the polyadenylation signal is identical. Therefore, the difference in transcript size between prostate and leukocytes is attributable to sequence differences upstream of the stretch identified by the prostate ESTs. An RT-PCR set up to amplify the constant domain portion of the TCR γ transcript identified the TCRC γ 1 gene. The slightly larger TCRC γ 2 is not expressed in LNcaP. Variable domain (V γ)- to constant domain (C γ)-spanning RT-PCRs did not yield any product, indicating that V γ is not part of the prostate-specific TCR γ transcript.

LNcaP Has Not Undergone VJ Gene Rearrangement in the TCR γ Locus. Because RT-PCRs intending to amplify the variable domain of TCR γ did not yield any product, we next analyzed the TCR γ locus. During the development of $\gamma\delta$ T-cells, the TCR loci undergo V(D)J gene rearrangements to bring together the gene segments that make up the variable domain of the receptor. To address whether LNcaP cells have undergone TCR γ VJ gene rearrangement, PCRs were carried out on genomic DNA by using combinations of TCRV γ and TCRJ γ primers, to cover every possible rearrangement (see *Materials and Methods*). None of the primer combinations yielded any PCR product, showing that LNcaP cells have not undergone VJ gene rearrangement of the TCR γ locus. The fact that TCR γ VJ rearrangement has not taken place in prostate epithelial cells shows that the prostate expression is different from that of mature $\gamma\delta$ T-lymphocytes.

Prostate Epithelial Cells Express a TCR (JC) γ Transcript. Because the identified prostate TCR γ transcripts consist of C γ but not of any V γ gene segment, we next analyzed what sequence is upstream of C γ 1. RNA primer-extension and 5'RACE PCR were carried out to obtain the starting point of transcription. The primer-extension experiment conducted on LNcaP mRNA showed a predominant band of \approx 128 nucleotides with minor bands in the 130–135 nucleotide area (Fig. 4). Because the reverse transcription started 75 bases from the




FIG. 1. Hybridization analysis of TCR γ mRNA expression. (A) Multiple tissue dot blot showing differential expression of human TCR γ . Positive tissues are prostate (C7), small intestine (E3), spleen (E4), thymus (E5), peripheral leukocyte (E6), lymph node (E7), bone marrow (E8), and lung (F2). (B) Northern blot showing TCR γ transcript sizes in normal tissues. Two TCR γ transcripts expressed in prostate are 1.1 and 2.8 kb whereas the predominant transcript in spleen, thymus, and peripheral blood leukocytes is 1.5 kb. The film was exposed for 20 hours.




FIG. 2. Northern blot analysis of TCR $\gamma\delta$ expression. (A) A TCR γ constant domain (TCR C γ) cDNA probe shows the 1.1- and 2.8-kb prostate-specific transcripts (compare with Fig. 1B). The film was exposed for 20 hours. (B) A TCR δ constant domain (TCR C δ) cDNA probe reveals that TCR δ mRNA is not expressed in prostate whereas expression is seen in spleen, thymus, and peripheral blood leukocytes. The film was exposed for 50 hours. (C) A TCR C γ cDNA probe shows that the LNCaP cell line expresses TCR γ whereas the PC-3 cell line does not. The film was exposed for 20 hours. Human β -actin mRNA expression was analyzed as a control.

5' end of C γ 1 (see *Materials and Methods*), the transcript has ≈ 53 nucleotides upstream of C γ 1. The 5' RACE PCR conducted on LNCaP cDNA revealed one specific PCR product. The amplified product was found to contain a J γ 1.2 gene segment, correctly spliced to the C γ 1 gene segments. A number of clones isolated by RACE PCR were sequenced. They initiated close to the start site defined by the primer extension experiment. A somewhat variable starting point of transcription is consistent with the identification of minor bands slightly larger than the predominant one in the primer-extension experiment. An illustration of how the prostate TCR γ is transcribed and spliced is shown in Fig. 5A. The nucleotide sequence of the TCR γ transcript, as obtained from LNCaP, is shown in Fig. 5B. The composite sequence is $1,020 \pm 3$ nucleotides long. It contains ≈ 53 bases from the J γ 1.2 gene segment, 519 bases of C γ 1, followed by 448 bases of untranslated sequence containing a polyadenylation signal and poly(A) sequence at the 3' end.

In Vitro Translation of the Prostate-Specific TCR γ Transcript. The prostate transcript has four translational initiation codons (ATG) in the original TCR γ reading frame that are double underlined in Fig. 5B. Calculated protein sizes for the four different start points are 12.8, 12.0, 6.7, and 3.2 kDa,

respectively. To analyze the translational activity of the prostate transcript, *in vitro* transcription-coupled translation was carried out by using full-length prostate TCR γ cDNA. Two proteins of ≈ 8 and 13 kDa were obtained (Fig. 6, lane 1). Negative control reactions did not yield any protein product.

DISCUSSION

Specific Expression of TCR γ Transcripts in Epithelial Cells of the Prostate. We have identified expression of T-cell receptor γ chain (TCR γ) mRNA in human prostate and have shown that it originates from epithelial cells of the prostate and not from infiltrating $\gamma\delta$ T-lymphocytes. We also demonstrate that the T-cell receptor δ chain (TCR δ) gene is silent in prostate. TCR γ mRNA is expressed in epithelial cells within the acinar ducts of the prostate as well as in prostate cancer. Two TCR γ transcripts of 1.1 and 2.8 kb are present in human prostate. They are different in size compared with the 1.5-kb TCR γ transcript found in spleen, thymus, and peripheral blood leukocytes. The TCR $\gamma\delta$ mRNA expression profile suggests that the transcription in prostate does not follow the usual pathway of $\gamma\delta$ T-lymphocytes. The prostate TCR γ expression was initially discovered by analysis of the publicly available




FIG. 3. RNA *in situ* hybridization on paraffin-embedded tissue sections using a TCR γ (C γ 1-3'UTR) anti-sense, ³⁵S-labeled riboprobe. The left panel photos are from dark field microscopy whereas the corresponding right panel photos are from in bright field microscopy. The bright grains shown in pictures taken in dark field are signals of RNA hybridization. (A) Prostate tissues from a 67-year-old man showing positive acinar epithelial cells and negative stromal cells ($\times 5$). (B) Bright field of A. (C) Higher magnification ($\times 40$) showing positive areas in the lower right corner. (D) Bright field of C. (E) Kidney tissues showing no RNA hybridization ($\times 5$). (F) Bright field of E.

EST database. Our results show that EST clustering is a powerful tool to identify novel and unexpected gene expression. The prostate ESTs representing the TCR γ transcript are all from cDNA libraries made from cells isolated by laser capture microdissection (10). The fact that the TCR γ transcripts proved to originate from prostate epithelial cells and not from infiltrating $\gamma\delta$ T-lymphocytes verifies that microdissection is a valuable technique to procure pure cell subpopulations from specific microscopic regions of tissues.

The Prostate TCR(JC) γ Transcript. The prostatic adenocarcinoma cell line, LNCaP, which was isolated from a lymph node metastasis (11), expresses readily detectable levels of the 1.1-kb prostate-specific TCR γ transcript. The expression in LNCaP cells shows that the transcript originates from epithelial cells and that it can be carried on during the development of a prostatic malignancy. The LNCaP transcript consists of ≈ 53 bases of the J γ 1.2 gene segment, the three C γ 1 exons, and the untranslated sequence followed by poly(A) sequence. The prostate transcript is different from the mature T-lymphocyte transcript in that it lacks a V γ gene segment and that it is initiated within the intronic sequence directly upstream of J γ 1.2 (data not shown). The promoter driving the prostate




FIG. 4. Primer-extension of LNCaP mRNA. The reverse primer anneals in the constant domain of TCR γ , starting 75 nucleotides from the 5' end of C γ 1. The reverse transcription stopped at ≈ 128 nucleotides, indicated by the arrow, revealing that the transcript is initiated ≈ 53 nucleotides upstream of C γ 1. The lane with TCR γ reverse transcription of LNCaP was exposed for 72 hours whereas the marker lane was exposed for 8 hours.





FIG. 5. The prostate TCR γ transcript. (A) Illustration on how the prostate TCR γ is transcribed and spliced. The transcript consists of a J γ 1.2 segment, the three exons of C γ 1, followed by untranslated sequence. (B) Nucleotide sequence of the TCR γ transcript as obtained from LNCaP cDNA. The starting point of transcription (underlined) is within the 10 first nucleotides of the J γ 1.2 segment. The four translational initiation codons (ATG) in the original TCR γ reading frame are double underlined. The sequence data is available from the European Molecular Biology Laboratory/GenBank/DNA Data Base in Japan under accession no. AF151103.

TCR γ transcript and its mechanism of activation in prostate epithelial cells are under investigation. The 2.8-kb prostate-specific TCR γ transcript is very faint in LNCaP, and the 5' RACE PCR experiment did not retrieve any product consistent with a 2.8-kb transcript. Therefore, the 2.8-kb transcript needs further study.

Comparison with TCR (JC) γ Transcripts in T-Lymphocytes. Many studies have shown that it is possible to detect TCR gene transcription before, or concomitant with, the onset of V(D)J rearrangement in hematopoietic cells (12-15). The TCR γ gene has been reported to be transcriptionally active in murine bone marrow-resident T-lymphocyte precursor cells with unrearranged γ loci, resulting in sterile TCR C γ transcripts (12). In addition, expression of unrearranged TCR V γ transcripts also have been reported during ontogeny (16). Sterile transcription of TCR and Ig gene segments has so far been limited to cells from the lymphoid lineages (17). Fur-




FIG. 6. *In vitro* transcription-coupled translation analysis of the prostate TCR γ . Two proteins with estimated sizes of 8 and 13 kDa were obtained (lane 1). Negative control reactions using the empty vector (lane 2) did not yield any protein product.

thermore, activation of germline transcription at nearly all TCR and Ig loci temporally correlates with activation of locus recombination (15–18). We have shown, by independent experiments using genomic DNA and cDNA, that recombination has not taken place of the TCR γ locus of prostate epithelial cells. Therefore, the expression of the TCR (JC) γ transcript in prostate epithelium does not correlate with recombination, and it may serve a different function than the sterile transcripts observed in T-lymphocyte precursor cells.

The Possibility of a Novel Prostate-Specific Protein in the TCR γ Locus. The prostate TCR γ transcript is highly expressed, and we hypothesize that there is an underlying, biologically important reason. The fact that VJ gene rearrangement has not taken place in the TCR γ locus of prostate epithelial cells excludes the possibility that a mature TCR γ chain protein is made. We also exclude the possibility that a TCR γ constant domain protein is made without the TCR γ variable domain because no translational initiation codon (ATG) is found upstream of C γ . In TCR γ chain proteins, a J γ segment encodes 16–20 amino acids of the variable domain whereas the major part of the variable domain is encoded by one of the V γ segments. Unless the amino acids encoded by a J γ segment are combined with amino acids encoded by a V γ segment, they cannot function as a TCR in MHC recognition. This raises the possibility of a novel prostate-specific protein, encoded from within C γ . Our hypothesis is

that one of the ATG codons in the original TCR γ reading frame initiates translation, although a different reading frame or a less frequently used initiation codon may be used. The *in vitro* transcription-coupled translation experiment using prostate TCR γ cDNA reveals that the transcript is fully functional. Two proteins were obtained. The 13-kDa protein most likely originates from the first double underlined ATG in Fig. 5B, which yields a calculated protein size of 12.8 kDa. The 8-kDa protein could originate from the third double underlined ATG, calculated size of 6.7 kDa, or from the first initiation codon in the second reading frame. We are currently investigating the nature of the protein encoded by the prostate-specific TCR γ transcript. In conclusion, the fact that prostate epithelial cells, or that any non-lymphoid-derived cell type, express high level of a transcript from a gene that was thought to be exclusively expressed by cells from the lymphoid lineage, is a highly unexpected discovery.

We thank Drs. Donna Peehl, Alfred Johnson, Michael Emmert-Buck, and Mark Raffeld for helpful comments and discussions. Magnus Essand is sponsored in part by the Swedish Cancer Society.

- Vasmataz, G., Essand, M., Brinkmann, U., Lee, B. K. & Pastan, I. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 300–304.
- Rabbitts, T. H., Lefranc, M.-P., Stinson, M. A., Sims, J. E., Schroder, J., Steinmetz, M., Spurr, N. L., Solomon, E. & Goodfellow, P. N. (1985) *EMBO J.* **4**, 1461–1465.
- Bensmana, M., Mattei, M. G. & Lefranc, M.-P. (1991) *Cytogenet. Cell Genet.* **56**, 31–32.
- Lefranc, M.-P., Chuchana, P., Dariavach, P., Nguyen, C., Huck, S., Brockly, F., Jordan, B. & Lefranc, G. (1989) *Eur. J. Immunol.* **19**, 989–994.
- Lefranc, M.-P. & Rabbitts, T. H. (1990) *Res. Immunol.* **141**, 565–577.
- Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A. & Struhl, K. (1995) *Current Protocols in Molecular Biology* (Wiley, New York).
- George, C. P. & Kadonaga, J. T. (1996) in *A Laboratory Guide to RNA: Isolation, Analysis and Synthesis*, ed. P. A. Krieg. (Wiley-Liss, New York), pp. 133–139.
- Krangel, M. S., Band, H., Hata, S., McLean, J. & Brenner, M. B. (1987) *Science* **237**, 64–67.
- Littman, D. R., Newton, M., Crommie, D., Ang, S. L., Seidman, J. G., Gettner, S. N. & Weiss, A. (1987) *Nature (London)* **326**, 85–88.
- Emmert-Buck, M. R., Bonner, R. F., Smith, P. D., Chuaqui, R. F., Zhuang, Z., Goldstein, S. R., Weiss, R. A. & Liotta, L. A. (1996) *Science* **274**, 998–1001.
- Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H., Chu, T. M., Mirand, E. A. & Murphy, G. P. (1983) *Cancer Res.* **43**, 1809–1818.
- Wang, T. G., Lybarger, L., Soloff, R., Dempsey, D. & Chervenak, R. (1996) *Mol. Immunol.* **33**, 957–964.
- Shimamura, M. & Ohta, S. (1995) *Eur. J. Immunol.* **25**, 1541–1546.
- Villey, I., Quartier, P., Selz, F. & de Villartay, J. P. (1997) *Eur. J. Immunol.* **27**, 1619–1625.
- Sikes, M. L., Gomez, R. J., Song, J. & Oltz, E. M. (1998) *J. Immunol.* **161**, 1399–1405.
- Goldman, J. P., Spencer, D. M. & Raulet, D. H. (1993) *J. Exp. Med.* **177**, 729–739.
- Lauzurica, P. & Krangel, M. S. (1994) *J. Exp. Med.* **179**, 1913–1921.
- Sleckman, B. P., Gorman, J. R. & Alt, F. W. (1996) *Annu. Rev. Immunol.* **14**, 459–481.